Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Deferred Taxes (2020 - 2025)

Historic Deferred Taxes for Catalyst Pharmaceuticals (CPRX) over the last 6 years, with Q3 2025 value amounting to -$2.4 million.

  • Catalyst Pharmaceuticals' Deferred Taxes fell 12815.7% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$217000.0, marking a year-over-year decrease of 10196.2%. This contributed to the annual value of $9.4 million for FY2024, which is 4731.17% down from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Deferred Taxes of -$2.4 million as of Q3 2025, which was down 12815.7% from $2.4 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Deferred Taxes high stood at $13.9 million for Q3 2023, and its period low was -$2.7 million during Q4 2021.
  • Moreover, its 5-year median value for Deferred Taxes was -$883000.0 (2023), whereas its average is $804789.5.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Deferred Taxes plummeted by 26902.71% in 2021, and later surged by 159282.66% in 2023.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Deferred Taxes stood at -$2.7 million in 2021, then skyrocketed by 53.19% to -$1.3 million in 2022, then surged by 31.28% to -$883000.0 in 2023, then tumbled by 189.35% to -$2.6 million in 2024, then grew by 5.4% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q3 2025, $2.4 million for Q2 2025, and $2.3 million during Q1 2025.